Ginkgo Biloba Extract Supplier — 24/6 Standardized & 4:1/10:1/20:1 Ratio | B2B Sourcing Guide

Written by Jonathan, Valeherb · Reviewed by Dr. Xiaoyan Qiu · Updated April 2026

Not all ginkgo material is equivalent — the gap between a standardized extract and generic ginkgo powder is wide enough to determine whether a finished formula can support its label specification. The industry benchmark is well-established: ginkgo biloba extract standardized to 24% flavone glycosides and 6% terpene lactones (the “24/6 standard”). Valeherb supplies both the 24/6 standardized extract and ratio extracts (4:1, 10:1, 20:1, HPLC fingerprint available). This guide covers the science behind the standard, the published research, and what to require when sourcing bulk material.

The 24/6 Standard: What It Means and Why It Matters

Raw ginkgo leaves contain highly variable concentrations of bioactive compounds — influenced by soil, harvest timing, leaf age, and processing. Standardization reduces that variability by concentrating two compound classes into a defined, reproducible ratio:

This ratio reflects the naturally occurring compound balance in high-quality Ginkgo biloba leaf material and is the composition used across the most cited clinical trials, including those using the proprietary reference extract EGb761. EGb761 is the reference extract against which standardized ginkgo extracts are commonly compared, and its trials at 120 mg daily form the primary research base for cognitive and circulatory studies.^[3]

Two Supply Forms

Note that the published cognitive research rests on the 24/6 (EGb761-type) composition; it does not automatically transfer to ratio extracts, which are characterised by HPLC fingerprint rather than the 24/6 marker percentages.

Published Research: What the Studies Show

Cognitive Function & Memory

A Cochrane systematic review by Birks & Grimley Evans (2009) analyzing 36 trials reported that standardized ginkgo biloba extract was associated with improvements in cognitive measures — including memory recall, processing speed, and attention — versus placebo across adult study populations.^[1] The trials used standardized extract at 120–240 mg daily, with 120 mg the most consistently studied dose.

Circulation Research

Terpene lactones — specifically ginkgolides A and B — are characterised in research as platelet-activating factor (PAF) inhibitors. Through reduced PAF-mediated platelet aggregation and effects on vascular tone, standardized ginkgo extract has been studied in the context of peripheral circulation.^[2]

Antioxidant & Neuroprotective Activity

Flavone glycosides are studied for scavenging reactive oxygen species (ROS) — an antioxidant mechanism characterised in research relevant to neuronal tissue, and an area of interest for topical and cosmeceutical applications where flavonoid preparations are studied against UV-induced oxidative stress in skin.^[1]

Formulation Applications

• Cognitive & nootropic supplements: The primary application. A common format is 120 mg standardized extract per capsule. Nootropic formulations frequently pair ginkgo with Bacopa monnieri, Lion’s mane, or phosphatidylserine
• Circulation-category supplements: Standardized extract at 120–240 mg/day formulation reference. Common in products for older-adult and general-wellness categories
• Cosmeceuticals & dermaceuticals: Flavone glycosides applied topically are studied for free-radical scavenging and skin-barrier support. Water-soluble extract grades required for serum and emulsion formats
• Functional foods & beverages: Heat-stable extract grades required; ginkgo’s mild bitter profile can be masked with natural flavor systems. Ratio extracts (4:1, 10:1, 20:1) are commonly used in this category

A frequent request we receive is for ginkgo biloba bulk extract for nootropic formulations. In our experience the most important specification discussion is the terpene lactone breakdown — clients building premium cognitive products want ginkgolide B confirmed separately, as it is the most-studied PAF inhibitor among the terpene lactones.

Doses Used in Published Research

The figures above are doses used in published clinical research, provided as a formulation reference only — not treatment recommendations or dosing instructions for any condition. Finished-product dosing and claims are the marketer’s responsibility under applicable regulations.

Sourcing Criteria: What Every B2B Buyer Should Require

Regulatory Guidance

• US (DSHEA): Any structure/function claim on the finished product is the marketer’s responsibility to substantiate and must carry the FDA disclaimer; antioxidant and general cognitive/memory support are the more readily supported areas. Circulatory and cerebrovascular claims sit close to disease territory and warrant caution. Disease treatment claims (e.g., dementia, stroke) require drug (NDA) approval
• EU: Ginkgo biloba leaf dry extract has a well-established-use monograph under the European Medicines Agency (EMA/HMPC/244112/2006)^[4] covering symptomatic relief in age-related cognitive impairment and peripheral arterial conditions — a strong regulatory background, though this is the status of the herbal medicinal product, not a claim for a supplement
• Germany (Commission E): Approved for symptomatic relief in dementia syndromes and intermittent claudication — the foundational phytomedicine approval that preceded the EMA monograph (regulatory background, not a supplement claim)

References